Pacira | PCRX - Cash And Equivalent


Pacira reported $144.31M in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
Astellas Pharma JPY 188.37B 8.51B Mar/2025
Bristol-Myers Squibb USD 9.57B 635M Mar/2026
Cara Therapeutics USD 20.73M 684K Dec/2025
Coherus Biosciences USD 88.88M 14.47M Dec/2025
Heron Therapeutics USD 26.12M 2.53M Mar/2026
Ironwood Pharmaceuticals USD 220.47M 5.01M Mar/2026
J&J USD 21.69B 1.98B Mar/2026
Ligand Pharmaceuticals USD 115.08M 59.85M Mar/2026
Nektar Therapeutics USD 15.12M 25.92M Dec/2025
Novo Nordisk A/S DKK 18.44B 5.78B Jun/2025
Omeros USD 1.9M 2.36M Jun/2025
Pacira USD 144.31M 14.24M Mar/2026
Perrigo USD 531.6M 99.5M Dec/2025
Pfizer USD 1.7B 561M Mar/2026
Supernus Pharmaceuticals USD 184.87M 56.42M Mar/2026
Teva Pharmaceutical Industries USD 3.56B 1.35B Dec/2025
Xeris Pharmaceuticals USD 111.75M 708K Mar/2026
Xoma USD 143.9M 7.68M Jun/2024
Zoetis USD 1.94B 369M Mar/2026